ERBB2 and breast cancer: In the future, a tolerance model, such as the HER2-transgenic FVB mouse model that is tolerant to the HER2 antigen and causes spontaneous HER2-overexpressing breast cancer and then metastases, should be employed to generate clinically relevant result.